These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8174197)

  • 21. Mercury induces regional and cell-specific stress protein expression in rat kidney.
    Goering PL; Fisher BR; Noren BT; Papaconstantinou A; Rojko JL; Marler RJ
    Toxicol Sci; 2000 Feb; 53(2):447-57. PubMed ID: 10696793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cisplatin on calcium uptake by rat kidney cortical mitochondria.
    Gemba M; Nakatani E; Teramoto M; Nakano S
    Toxicol Lett; 1987 Oct; 38(3):291-7. PubMed ID: 3660432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of cisplatin nephrotoxicity.
    Weiner MW; Jacobs C
    Fed Proc; 1983 Oct; 42(13):2974-8. PubMed ID: 6684595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
    Campbell AB; Kalman SM; Jacobs C
    Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection against cisplatin-induced lipid peroxidation and kidney damage by procaine in rats.
    Zhong LF; Zhang JG; Zhang M; Ma SL; Xia YX
    Arch Toxicol; 1990; 64(7):599-600. PubMed ID: 2073136
    [No Abstract]   [Full Text] [Related]  

  • 28. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
    Lagrange JL; Médecin B; Etienne MC; Pivot X; Cassuto-Viguier E; Renée N; Thyss A; Ferrero JM; Otto J; François E; Milano G
    Pharmacotherapy; 1997; 17(6):1246-53. PubMed ID: 9399607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity].
    Kitajima K; Fukuoka M; Kobayashi S; Kusunoki Y; Takada M; Negoro S; Matsui K; Sakai N; Ryu S; Takifuji N
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2517-23. PubMed ID: 3039920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes-induced protection from cisplatin nephrotoxicity is associated with impairment of energy-dependent uptake by renal cortex slices.
    Sarangarajan R; Cacini W
    Pharmacol Toxicol; 1997 Oct; 81(4):197-8. PubMed ID: 9353851
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical pharmacology of intraperitoneal cisplatin.
    Lopez JA; Krikorian JG; Reich SD; Smyth RD; Lee FH; Issell BF
    Gynecol Oncol; 1985 Jan; 20(1):1-9. PubMed ID: 4038390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Platinum concentrations in human tissue after administration of cisplatin].
    Tochigi T; Ono K; Yoshikawa K; Hoshi S; Orikasa S; Imai Y
    Gan To Kagaku Ryoho; 1988 Feb; 15(2):269-75. PubMed ID: 3341789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.
    Pujol JL; Cupissol D; Gestin-Boyer C; Bres J; Serrou B; Michel FB
    Cancer Chemother Pharmacol; 1990; 27(1):72-5. PubMed ID: 2173980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The protective effects of two hydration protocols against cisplatin nephrotoxicity].
    Guo JH; Song ST; Xu ZL
    Zhonghua Zhong Liu Za Zhi; 1994 Jan; 16(1):56-8. PubMed ID: 8033751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of platinum in the brain of mice treated with cisplatin and subjected to short-term hypoxia.
    Minami T; Ichii M; Okazaki Y
    J Pharm Pharmacol; 1996 May; 48(5):505-9. PubMed ID: 8799875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies on adequate intervals of cisplatin administration to ameliorate cisplatin-induced nephrotoxicity].
    Sakatoku H; Kawai K; Kamiya H; Sakurai M
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):239-46. PubMed ID: 3947105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans.
    Uozumi J; Ueda T; Yasumasu T; Koikawa Y; Naito S; Kumazawa J; Sueishi K
    Int Urol Nephrol; 1993; 25(3):215-20. PubMed ID: 8225820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
    Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E
    Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney.
    Sheikh-Hamad D; Cacini W; Buckley AR; Isaac J; Truong LD; Tsao CC; Kishore BK
    Arch Toxicol; 2004 Mar; 78(3):147-55. PubMed ID: 14551673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.